.png)
iCAD, a global medical technology leader providing innovative enhanced cancer detection and therapy solutions for more than 6,500 facilities worldwide, offers a wide range of powerful tools for clinicians to support cancer detection, while enhancing workflow efficiency. iCAD's Breast Health Solutions include the ProFound AI® platform, a high-performing, concurrent-read workflow solution built on the latest deep-learning artificial intelligence that rapidly analyzes each tomosynthesis image to detect malignant soft tissue densities and calcifications with unrivaled accuracy, and Density Assessment, which assists radiologists in determining the patient's appropriate breast density category. This powerful platform is scalable for new applications, including ProFound AI Risk, the first commercially available clinical decision support tool that uniquely combines age, breast density, the presence of masses and calcifications and their asymmetry, resulting in a highly accurate short-term risk estimation that is truly personalized for each woman.
ProFound AI for Digital Breast Tomosynthesis (DBT) is a sophisticated artificial intelligence (AI) software solution that is revolutionizing the way radiologists read mammography. In 2018, ProFound AI for DBT became the first artificial intelligence (AI) software for DBT, or 3D mammography, to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. This high-performing workflow solution features the latest in deep-learning artificial intelligence and is clinically-proven to offer critical benefits to radiologists and patients alike, including a 7% reduction in unnecessary patient recalls and a 52.7% reduction in reading time for radiologists. The latest version of ProFound AI, Version 3.0 offers a 10% improvement in specificity performance, compared to previous versions of the software.
We work passionately to provide precise, powerful healthcare solutions expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes.
For more information, visit www.icadmed.com.